DNAlite Therapeutics, Inc. — Form D
DNAlite Therapeutics, Inc. of SAN FRANCISCO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2022-04-15. The offering totals $8.9M, of which $5.6M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-04-15
- Form: D
- Accession: 0001922565-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $8.9M
- Amount sold: $5.6M
- Remaining: $3.3M
- Investors: 18
- Date of first sale: 2022-04-01
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-441983
Issuer
- Name: DNAlite Therapeutics, Inc.
- CIK: 0001922565
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 455 MISSION BAY BOULEVARD, SAN FRANCISCO, CA, 94158
- Phone: (713) 569-0302
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Mubhij Ahmad | Director | San Francisco, CA |
| Timothy Paul Day | Director | San Francisco, CA |
| Drew Cain Lanza | Director | San Francisco, CA |
| Andrew Cain McClary | Director | San Francisco, CA |
| David Cain Rabuka | Director | San Francisco, CA |
| Mubhij Ahmad | Executive Officer | San Francisco, CA |
More